ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: Travoprost 0.004% Ophthalmic Solution (Travatan)
Drug: Timolol 0.5% Ophthalmic Solution (Timoptic)

First Posted Date: 2008-09-30

Last Posted Date: 2010-03-02

Lead Sponsor: Alcon Research

Target Recruit Count: 111

Registration Number: NCT00763061

Locations: 🇺🇸
Alcon Call Center, Fort Worth, Texas, United States

Rotational Stability of the AcrySof® Toric

Not Applicable

Completed

Conditions: Cataract

Interventions: Device: AcrySof® Toric intraocular lens

First Posted Date: 2008-09-30

Last Posted Date: 2012-10-31

Lead Sponsor: Alcon Research

Target Recruit Count: 71

Registration Number: NCT00762216

Locations: 🇺🇸
Alcon Call Center, Fort Worth, Texas, United States

Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® Toric

Phase 4

Withdrawn

Conditions: Cataract

Interventions: Device: AcrySof® Toric IOL

First Posted Date: 2008-09-29

Last Posted Date: 2015-05-12

Lead Sponsor: Alcon Research

Registration Number: NCT00761488

Locations: 🇺🇸
Alcon Call Center, Fort Worth, Texas, United States

Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)

First Posted Date: 2008-09-29

Last Posted Date: 2012-04-26

Lead Sponsor: Alcon Research

Target Recruit Count: 705

Registration Number: NCT00761319

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Ocular Hypertension
Open-Angle Glaucoma

Interventions: Drug: Vehicle
Drug: AL-39256 Ophthalmic Suspension, 1%
Drug: Latanoprost Ophthalmic Solution, 0.005%

First Posted Date: 2008-09-29

Last Posted Date: 2014-07-15

Lead Sponsor: Alcon Research

Target Recruit Count: 104

Registration Number: NCT00761709

Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens

Phase 4

Completed

Conditions: Cataract

Interventions: Device: AcrySof Toric IOL

First Posted Date: 2008-09-26

Last Posted Date: 2012-01-16

Lead Sponsor: Alcon Research

Target Recruit Count: 120

Registration Number: NCT00760487

Locations: 🇺🇸
Alcon Call Center, Fort Worth, Texas, United States

Safety and Efficacy of Travoprost/Timolol BAC-free

Phase 3

Completed

Conditions: Ocular Hypertension
Open-Angle Glaucoma

Interventions: Drug: Travoprost 0.004%/Timolol 0.5% ophthalmic solution
Drug: Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution

First Posted Date: 2008-09-26

Last Posted Date: 2014-07-16

Lead Sponsor: Alcon Research

Target Recruit Count: 87

Registration Number: NCT00760539

Locations: 🇯🇵
Manabe Clinic, Hamura, Tokyo, Japan

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Phase 4

Terminated

Conditions: Intraocular Pressure

Interventions: Drug: Travoprost 0.004% + Brinzolamide 1.0%
Drug: Travoprost 0.004% + Tears Natural

First Posted Date: 2008-09-25

Last Posted Date: 2023-12-05

Lead Sponsor: Alcon Research

Target Recruit Count: 37

Registration Number: NCT00758342

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: Placebo eye drops
Drug: Brinzolamide 1% ophthalmic solution (Azopt)
Drug: Latanoprost 0.005% ophthalmic solution (Xalatan)

First Posted Date: 2008-09-25

Last Posted Date: 2014-01-13

Lead Sponsor: Alcon Research

Target Recruit Count: 86

Registration Number: NCT00759941

Locations: 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States

Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004% / Timolol maleate 0.5%

First Posted Date: 2008-09-25

Last Posted Date: 2016-11-22

Lead Sponsor: Alcon Research

Target Recruit Count: 36

Registration Number: NCT00759239

Locations: 🇬🇧
Western Eye Hospital, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy